Cardiovascular Devices Market: Growth, Size, Share, and Trends

Report Code MD 9240
Published in Jan, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Cardiovascular Devices Market by Product (Cardiac Imaging, Rhythm Management, Cardiac Assist Devices, Interventional Cardiology, Electrophysiology, Monitoring ), Indication (CAD, MI, CHF), End User (Hospitals & Clinics) - Global Forecast to 2029

Overview

The global cardiovascular devices market, valued at US$72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3%, reaching US$77.71 billion in 2024 and an impressive US$110.39 billion by 2029.

The growth of the cardiovascular devices market is primarily due to the increasing prevalence of CVD, the aging population, and the growing prevalence of risk factors like diabetes, hypertension, obesity, and sedentary lifestyle. Technological improvements, such as bioresorbable stents, drug-eluting stents, bioresorbable occluder and imaging systems, are significantly enhancing procedural efficacy and patient outcomes, making cardiovascular devices appealing and accessible. Countries in emerging economies are also focused on modernizing healthcare infrastructure with favourable investments in healthcare systems expected to fuel the adoption of cardiovascular devices. Additionally, the growing preference of patients towards minimally invasive procedures and remote monitoring owing to procedural benefits such as rapid diagnosis, shorter hospital stays rapid recovery time is also expected to boost the demand for these devices during the forecast period.

Cardiovascular Devices Market

Attractive Opportunities in the Cardiovascular Devices Market

Asia Pacific

The growth of the Cardiovascular devices market in the Asia Pacific region is driven by a combination of factors. lifestyle changes, has increased the prevalence of CVD in China, India, and Japan various initiatives undertaken by the government to manage CVD coupled with rising technological advancements and favorable healthcare expenditure in this region os expected to boost the demand for these devices.

The key factors driving market growth include the increasing incidence of cardiovascular diseases, often associated with aged population demographics, unhealthy lifestyles, require advanced treatments for cardiovascular conditions.

The high growth potential of emerging economies are expected to provide opportunities to market players during the forecast period.

The Asia pacific cardiovascular devices devices market is projected to reach USD 27.499 billion by 2029, growing at a CAGR of 8.85% during the forecast period

Stringent regulatory requirements for product approvals are expected to restrain the market growth to a certain extent.

Global Cardiovascular Devices Market Dynamics

DRIVER: Increasing prevalence of cardiovascular diseases and subsequent increase in usage of cardiovascular devices

As CVDs are main factor for death worldwide. Therefore, rising occurrence of CVDs is a major driver that drives the cardiovascular devices market. Sedentary lifestyle, aging population, and increasing rates of obesity have also contributed to the growing incidence of CVDs, that requires advanced diagnostic and therapeutic solutions. Technological advancements, better efficacy and outcomes of cardiovascular devices like pacemakers, stents, and ICDs, increase their demand. With the development of minimally invasive procedures, bioresorbable stents, and remote monitoring capabilities, the cardiovascular devices are becoming more acceptable to the patients and the healthcare providers. Additionally, a high healthcare expenditure and encouragement through positive governmental policies for early diagnosis and treatment for diseases enhance its usage both in the developed and the developing nations. This growing utilization also prompts the expansion of healthcare infrastructure, enabling broader adoption.

RESTRAINT: Stringent regulatory guidelines for product approval

Stringent regulations for products approvals pose as a challenge to the growth of cardiovascular devices market. Although, these regulations are incorporated to ensure the safety and effectiveness of medical devices, lengthy processes for approval lead to delays and additional costs for manufacturers. This significantly prolong the period required to bring innovative devices to the market, therefore, impacting market dynamics. Manufacturers face the dual pressure of showing clinical efficacy through large-scale research studies and maintaining strict quality standards. While these measures are necessary to protect the health of patients, they exert a huge financial and operational burden on small companies. This may prevent them from launching new devices in the market quickly, which can reduce competition in the market and may even kill innovation.

 

OPPORTUNITY: Projected growth in the elderly population

The projected growth in the elderly population act as an important opportunity for the cardiovascular devices market as the increased prevalence of CVDs is among older individuals. old age is a major risk factor for cardiac conditions such as coronary artery disease, heart failure, arrhythmias, and valvular disorders. The physiological changes in the cardiovascular system, such as arterial stiffening and reduced vascular elasticity, render older individuals more susceptible to the above diseases. The global population aged 65 years and older is expected to increase two-fold by 2050. As a result of this, the demand for advanced diagnostic, monitoring, and therapeutic cardiovascular devices will increase. Further, minimally invasive technologies will be more adopted since they reduce the recovery time and are best suited for the elderly patient with comorbidities. Governments and healthcare systems across the globe are now focusing their investments on geriatric care, thereby supporting cardiovascular devices adoption. Personalized medicine is also contributing to this growth as it allows the elderly to have device-based interventions tailored for them.

CHALLENGES: Adverse effects and complications with usage of implantable cardiovascular devices

Devices such as pacemakers, defibrillators, and stents are crucial in the management of cardiovascular conditions. However, their use can be associated with several complications, such as device malfunction, infection, blood clot, or an allergic reaction. These risks often create apprehension among patients and healthcare providers of their usage. Therefore, can prevent the widespread use of these technologies. Severe infections may necessitate removal of the device and other surgical interventions, raising the cost of health care and prolonging the time needed for the patient's recovery. Device malfunctions or failures, though rare, have significant health implications such as misplacement of pacing or shock in pacemakers and defibrillators that, if not corrected in a timely manner, will prove fatal

Global Cardiovascular Devices Market Ecosystem Analysis

The cardiovascular devices market ecosystem involves various stakeholders and technologies.

Cardiovascular Devices Market
 

The Interventional cardiology market dominates the cardiovascular devices market by holding the largest share.

The interventional cardiology devices continue to remain in top in the cardiovascular devices market because of the crucial role these play in the minimally invasive procedures applied during diagnosis and treatment of cardiovascular disorders. Devices such as stents, catheters, angioplasty balloons, and atherectomy systems are commonly used in interventions, such as PCI, the gold standard in treating coronary artery disease. The rising prevalence of cardiovascular diseases due to demographic aging, unhealthy lifestyles, and more people having diabetes and being obese and advancements in technology also contribute to the trend. These devices also align well with the increasing demand for minimally invasive procedures, due to shorter recovery times, fewer hospital stays, and less overall cost compared to traditional open-heart surgeries. Moreover, the strong clinical evidence of their effectiveness coupled with favourable reimbursement policies in many regions has further aided their market position.

The Structural Heart disease to grow at the highest GAGR in cardiovascular devices market.

The structural heart disease segment is expected to grow at the highest CAGR in the cardiovascular devices market because of various factors. For instance, a rapidly aging global population will increasingly lead to the incidence of structural heart conditions, including aortic stenosis and mitral regurgitation, which are typically amenable to interventional treatment. In this respect, minimally invasive technologies in the form of transcatheter aortic valve replacement (TAVR) and mitral valve repair devices have improved over the past few years with safer access to these procedures. Higher awareness and early detection in most geographies along with more beneficial reimbursement policies support higher adoption demand for this market. Ongoing R&D investments in novel solutions boost innovation and hence improve device effectiveness along with outcomes for patients. Together, these trends establish structural heart disease treatments as an essential and fast-moving area.

The hospitals & Clinics in end user segment is expected to dominate the market, during the forecast period.

The hospitals segment is expected to dominate the market by end users in the cardiovascular devices market. The expanding population suffering from cardiovascular diseases will necessitate a higher demand for minimally invasive treatment procedures. Improvements in interventional technologies also allow hospitals to provide wide-ranging specialized services such as advanced coronary and structural heart interventions. Hospital-based catheterization labs and specialized cardiac centers are also established worldwide. The growing investments in healthcare infrastructure and the surge in the population of cardiologist specialists are additional factors contributing to the demand for interventional cardiology devices in this end-user segment during the forecast period.

North America region holds the largest share in the cardiovascular devices market.

North America holds the largest share, owing to the increasing prevalence of CVD, established healthcare systems, and the development of medical technology. The region benefits significantly from a high adoption rate of innovative procedures, which include minimally invasive interventions and catheter-based treatments, contributing to improved patient outcomes and quicker recovery times. Besides, high expenditure on R&D, along with an aging population, is fuelling demand for cardiovascular devices. Government initiatives to increase access to healthcare and health-conscious lifestyles are rising in North America, which is also expected to fuel the adoption of cardiovascular devices.

HIGHEST CAGR MARKET IN 2024-2029
US FASTEST GROWING MARKET IN THE REGION
Cardiovascular Devices Market

Recent Developments of Cardiovascular Devices Market

  • In June 2024, Abbott today announced it has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. The AVEIR DR leadless pacemaker system utilizes a new method of delivering dual chamber therapy as it is comprised of two unique devices – one that paces the right ventricle (AVEIR VR) and one that paces the right atrium (AVEIR AR). Each device is roughly one-tenth the size of a traditional pacemaker and smaller than a AAA battery.
  • In September 2024, Boston Scientific Corporation received Japan's Pharmaceuticals and Medical Device Agency (PMDA) approval for the FARAPULSE Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), is a novel alternative to standard-of-care thermal ablation treatment.
  • In July 2024, Edwards Lifesciences Corporation decided to exercise its option to acquire Innovalve Bio-Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017.
  • In February 2024, Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive the US FDA approval for treating tricuspid regurgitation (TR).

Key Market Players

Want to explore hidden markets that can drive new revenue in Cardiovascular Devices Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD)
Segments covered Cardiovascular devices – Product, Indication End user and Region
Geographies covered Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa.

 

Key Questions Addressed by the Report

What are the major players in the cardiovascular devices market?
Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), BIOTRONIK SE & Co. KG (Germany), GE Healthcare Technologies, Inc. (US), Siemens Healthineers AG (Germany), Johnson & Johnson (US), Baxter International Inc (US), Getinge AB (Sweden), Lepu Medical Technology (Beijing) Co., Ltd (China), Nihon Kohden Corporation (Japan), MicroPort Scientific Corporation (China), Japan Lifeline Co., Ltd. (Japan), AngioDynamics, Inc.US), Artivion Inc (US), Sahajanand Medical Technologies Limited (India), W.L. Gore & Associates, Inc (US)
What product types have been included in the cardiovascular devices market report?
Cardiac imaging and diagnostic devices, Cardiac rhythm management devices, interventional cardiology devices, Cardiac assist devices, electrophysiology devices, External support devices, Monitoring devices.
Which geographical region is dominating in the cardiovascular devices market?
The cardiovascular devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America holds the largest share and Asia Pacific registers the highest growth during the forecast period.
Which end user segments have been included in the cardiovascular devices market report?
Hospitals & Clinics, Diagnostic laboratories, Ambulatory surgical centre and others.
What is the total CAGR expected to be recorded for the cardiovascular devices market during 2024-2029?
The CAGR is expected to record a CAGR of 7.3 % from 2024-2029

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Cardiovascular Devices Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
24
EXECUTIVE SUMMARY
41
PREMIUM INSIGHTS
67
MARKET OVERVIEW
89
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 INDUSTRY TRENDS
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGY
    COMPLEMENTARY TECHNOLOGY
    ADJACENT TECHNOLOGY
  • 5.5 PORTER'S FIVE FORCE ANALYSIS
  • 5.6 REGULATORY LANDSCAPE
    REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATION
  • 5.7 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR THE CARDIOVASCULAR DEVICES MARKET
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.8 TRADE ANALYSIS
  • 5.9 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
    AVERAGE SELLING PRICE TREND OF CARDIOVASCULAR DEVICES PRODUCTS, BY REGION
  • 5.10 KEY CONFERENCES & EVENTS 2024-2025
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN THE BUYING PROCESS
    BUYING CRITERIA
  • 5.12 UNMET NEEDS/END USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET
  • 5.13 IMPACT OF GEN AI ON CARDIOVASCULAR DEVICES MARKET
  • 5.14 ECOSYSTEM/ MARKET MAP
  • 5.15 CASE STUDY ANALYSIS
  • 5.16 SUPPLY/VALUE CHAIN ANALYSIS
  • 5.17 ADJACENT MARKET ANALYSIS
  • 5.18 TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS
  • 5.19 CARDIOVASCULAR DEVICES MARKET, INVESTMENT, AND FUNDING SCENARIO
  • 5.20 CARDIOVASCULAR DEVICES MARKET, R&D PIPELINE ANALYSIS
CARDIOVASCULAR DEVICES MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
98
  • 6.1 INTRODUCTION
  • 6.2 CARDIAC IMAGING AND DIAGNOSTIC DEVICE
    ELECTROCARDIOGRAM (ECG) DEVICE ( RESTING, STRESS, HOLTER MONITORS, MOBILE ECG )
    CARDIAC ULTRASOUND SYSTEM/ECHOCARDIOGRAM (INCLUDES DOPPLER FETAL MONITOR)
    CARDIAC COMPUTERISED TOMOGRAPHY (CT) SCAN
    CARDIAC MAGNETIC RESONANCE IMAGING (MRI)
    DIAGNOSTIC CATHETER
    NUCLEAR CARDIOLOGY SYSTEM (PET,SPECT)
  • 6.3 CARDIAC RHYTHM MANAGEMENT DEVICE
    PACEMAKER (SINGLE CHAMBER, DUAL CHAMBER)
    IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
    CARDIAC RESYNCHRONIZATION THERAPY DEVICE (CRT-P, CRT-D)
  • 6.4 INTERVENTIONAL CARDIOLOGY DEVICE
    CORONARY STENT (BARE METAL, DRUG ELUTING,BIOABSORBABLE, COVERED)
    HEART VALVE DEVICE (TRANSCATHETER, SURGICAL)
    OCCLUDER/CLOSURE DEVICE (ASD,VSD,PFO,PDA,LAA,VESSEL CLOSURE DEVICE)
    SURGICAL CATHETER ( ANGIOGRAPHY, DRINAGE, IVUS/OCT,GUIDING, BALLOON)
    GUIDEWIRE
    OTHER (CARDIAC GRAFT, ANNULOPLASTY RING, EMBOLIC PROTECTION DEVICE, CARDIAC SHEATH, SNARE)
  • 6.5 CARDIAC ASSIST DEVICE
    VENTRICULAR ASSIST DEVICE
    TOTAL ARTIFICIAL HEART
    IMPELLA
    INTRA AORTIC BALLOON PUMP
  • 6.6 ELECTROPHYSIOLOGY DEVICE
    EP CATHETER
    ABLATION SYSTEM ( RADIOFREQUENCY, CRYOABLATION)
    3D MAPPING SYSTEM
  • 6.7 EXTERNAL SUPPORT DEVICE
    EXTERNAL DEFIBRILLATOR
    EXTERNAL PACEMAKER
    CARDIAC COMPRESSION DEVICE
  • 6.8 MONITORING DEVICE
    BLOOD PRESSURE MONITOR
    PULSE OXIMETER
    INSERTABLE CARDIAC MONITOR /LOOP RECORDER
CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
115
  • 7.1 INTRODUCTION
  • 7.2 CORONARY ARTERY DISEASE
    ANGINA PECTORIS
    MYOCARDIAL INFRACTION
  • 7.3 ARRHYTHMIAS
    TACHYCARDIA
    BRADYCARDIA
  • 7.4 STRUCTURAL HEART DISEASE
    VALVULAR HEART DISEASE
    CONGENITAL HEART DISEASE
    CARDIOMYOPATHY
  • 7.5 CONGESTIVE HEART FAILURE
  • 7.6 INFLAMMATORY HEART DISEASE
    PERICARDITIS
    ENDOCARDITIS
    MYOCARDITIS
  • 7.7 OTHER CARDIOVASCULAR INDICATIONS
CARDIOVASCULAR DEVICES MARKET, BY END-USER, 2022-2029 (USD MILLION)
136
  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS & CLINICS
  • 8.3 DIAGNOSTIC LABORATORIES
  • 8.4 AMBULATORY SURGICAL CENTERS
  • 8.5 OTHERS
CARDIOVASCULAR DEVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
156
  • 9.1 INTRODUCTION
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR EUROPE
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST AND AFRICA
COMPETITIVE LANDSCAPE
182
  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.3 MARKET SHARE ANALYSIS
  • 10.4 VALUATION AND FINANCIAL METRICS OF KEY CARDIOVASCULAR DEVICES PRODUCTS VENDORS
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - DEVICE FOOTPRINT
    - APPLICATION TYPE FOOTPRINT
    - END-USER FOOTPRINT
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF KEY STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 10.7 COMPETITIVE SITUATION AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
  • 10.8 CARDIOVASCULAR DEVICES MARKET, BRAND/PRODUCT COMPARATIVE ANALYSIS
COMPANY PROFILES
197
  • 11.1 KEY PLAYERS
    ABBOTT LABORATORIES
    GE HEALTHCARE
    EDWARD LIFESCIENCES CORPORATION
    SIEMENS HEALTHINEERS
    MEDTRONIC PLC
    BOSTON SCIENTIFIC CORPORATION,
    JOHNSON AND JOHNSON SERVICES INC
    TERUMO CORPORATION
    BAXTER INTERNATIONAL INC
    WL GORE AND ASSOCIATES
    GETINGE AB
    KONINKLIJKE PHILLIPS NV
    NIHON KOHDEN CORPORATION
    LEPU MEDICAL TECHNOLOGY
    MICROPORT SCIENTIFC CORPORATION
    JAPAN LIFELINE CO LTD
    ANGIODYNAMICS INC
    ARTIVION
    BIOTRONIK SE & CO. KG
    SAHAJANAND MEDICAL TECHNOLOGIES LIMITED
    B.BRAUN SE
  • 11.2 OTHER PLAYERS
    CANON MEDICAL SYSTEMS CORPORATION
    PICARD MEDICAL COMPANY (SYNCARDIA)
    BPL MEDICAL TECHNOLOGIES PVT LTD
    LIFETECH SCIENTIFIC CORPORATION
    ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED
APPENDIX
225
  • 12.1 INSIGHTS OF INDUSTRY EXPERTS
  • 12.2 DISCUSSION GUIDE
  • 12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.4 AVAILABLE CUSTOMIZATION
  • 12.5 RELATED REPORTS
  • 12.6 AUTHOR DETAILS

This study involved four major activities in estimating the size of the cardiovascular devices market. Exhaustive secondary research was done to collect information on the market, peer market, and various child market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the cardiovascular devices market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the cardiovascular devices market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Breakdown of Primary Interviews

Cardiovascular Devices Market

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include Others include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2020: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=< USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The research methodology used to estimate the size of the cardiovascular devices market includes the following details.

The market sizing of the market was undertaken from the global side.

Country-level Analysis ( Only for North America): The size of the cardiovascular devices market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products and services in the overall cardiovascular devices market was obtained from secondary data and validated by primary participants to arrive at the total cardiovascular devices market. Primary participants further validated the numbers.

Geographic market assessment (by region): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends

Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall cardiovascular devices market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Global cardiovascular devices Size: Top-Down and Bottom Up Approach

Cardiovascular Devices Market

Data Triangulation

After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cardiovascular devices are medical equipments that encompass a wide range of products including medical instruments such as stents, pacemakers, telemetry, and defibrillators. These devices become most prevalent, particularly during surgical procedures, from minimally invasive ones to highly complex open-heart operations.The usage of these devices significantly improves and patient treatment and the quality of life. Cardiovascular devices are also evolving due to the use of more advanced materials and engineering, which is consistent with the increasing number of patients with heart diseases.

Stakeholders

  • Manufacturers of cardiovascular devices
  • Cardiovascular device distributors
  • Healthcare service providers
  • Various research associations related to cardiovascular devices
  • Research institutes
  • Venture capitalists and investors
  • Various research and consulting companies
  • World Health Organization (WHO)
  • Organization for Economic Co-operation and Development (OECD)
  • National Institutes of Health (NIH)
  • Centers for Disease Control and Prevention (CDC)
  • Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
  • White Papers, Journals/Magazines, and News Articles
  • Paid Databases, such as Factiva, D&B Hoovers, and Bloomberg Business

Report Objectives

  • To define, describe, segment, and forecast the cardiovascular devices market by product , indication & end user, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall cardiovascular devices market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the cardiovascular devices market in five main regions namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the cardiovascular devices market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the cardiovascular devices market
  • To benchmark players within the cardiovascular devices market using the competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

 

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Cardiovascular Devices Market

DMCA.com Protection Status